Phase 1 Norwalk Vaccine Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2009-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized, double blind, multi-site, study in healthy adults, comparing safety and immunogenicity of two dosage levels of Norwalk VLP Vaccine with adjuvant/excipients and with placebo controls

Primary Objective:

* Safety as determined by occurrence of local intranasal symptoms or other symptoms as reported by a self-administered memory aid for 7 days after each vaccination and hematology, blood chemistry and physical examinations performed by the clinical research staff
* Subjects will also be monitored for Serious Adverse Events (SAEs), and onset of any new medical conditions for 180 days following the last study vaccinations (Day 201).

Secondary Objectives

Evaluations of immunogenicity as determined by:

* Geometric mean titers and seroconversion rate of serum anti- Norwalk VLP IgG and IgA
* Stimulation of anti-Norwalk VLP IgA antibody secreting cells (ASC)
* Presence of antigen specific memory B-cell response

Cells will be collected and stored for possible future evaluation of Norwalk VLP-specific cell-mediated immune (CMI) responses

Study Hypothesis:

The incidence of adverse events after intranasal Norwalk VLP Vaccine will be the same as the incidence of adverse events after intranasal adjuvant/excipients alone. Norwalk VLP Vaccine and adjuvant/excipients will have a higher incidence of mild to moderate nasal adverse events compared to placebo but similar incidence of other adverse events.

Two doses of the 100 µg of Norwalk VLP Vaccine will be more immunogenic than two doses of 50 µg of Norwalk VLP Vaccine. The post-vaccination serum antibody responses, the number of antibody secreting cells (ASC) and IgG and IgA memory B-cell responses directed against Norwalk Virus antigen will be increased after Norwalk VLP Vaccine compared to adjuvant/excipients and to placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Norwalk Vaccine Study

NCT00973284

Acute Gastroenteritis Norwalk Virus Infection

COMPLETED PHASE1/PHASE2

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

NCT02142504

Norovirus Prevention

COMPLETED PHASE2

Bivalent Norovirus Vaccine Study

NCT01168401

Gastroenteritis

COMPLETED PHASE1

Norovirus Bivalent-Vaccine Efficacy Study

NCT01609257

Prevention From Norovirus Infection

COMPLETED PHASE1/PHASE2

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

NCT05992935

Norovirus Acute Gastroenteritis

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Norovirus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccine Arm 1

50 µg Norwalk VLP Vaccine + Adjuvant/Excipients

Group Type EXPERIMENTAL

Norwalk VLP Vaccine

Intervention Type BIOLOGICAL

intranasal, 50mcg, 2 doses--21 days apart

Vaccine Arm 2

100 µg Norwalk VLP Vaccine + Adjuvant/Excipients

Group Type EXPERIMENTAL

Norwalk VLP Vaccine

Intervention Type BIOLOGICAL

Intranasal, 100 mcg, 2 doses, 21 days apart

Adjuvant/Excipients (MPL)

14 mg chitosan, 3 mg mannitol, 3 mg sucrose, and 50 mcg MPL

Group Type ACTIVE_COMPARATOR

Adjuvant/Excipients

Intervention Type DRUG

intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart

Empty device

Empty device that contains no dry powder formulation. Actuation of the empty intranasal delivery device will deliver a puff of air per device.

Group Type SHAM_COMPARATOR

placebo

Intervention Type DEVICE

intranasal, puff of air, 2 doses, 21 days apart

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adjuvant/Excipients

intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart

Intervention Type DRUG

placebo

intranasal, puff of air, 2 doses, 21 days apart

Intervention Type DEVICE

Norwalk VLP Vaccine

intranasal, 50mcg, 2 doses--21 days apart

Intervention Type BIOLOGICAL

Norwalk VLP Vaccine

Intranasal, 100 mcg, 2 doses, 21 days apart

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed written informed consent
2. Age 18 - 50 years, inclusive
3. Good general health as determined by a screening evaluation within 30 days before administration of Norwalk VLP Vaccine, adjuvant/excipients or placebo
4. Expressed interest and availability to fulfill the study requirements
5. Agrees not to become pregnant from the time of study enrollment until at least 56 days after the last administration of Norwalk VLP Vaccine, adjuvant/excipients or placebo; if a woman is sexually active and capable of conception (i.e., no history of hysterectomy or tubal ligation), she must agree to use hormonal or barrier birth control. A woman is eligible if she is monogamous with a male who has had a vasectomy.
6. Demonstrated to be an H type-1 antigen secretor
7. Agrees not to participate in another clinical trial with an investigational product for the entire duration of the study (six months after the last study dose i.e. 201 days)
8. Agrees to storage of unused clinical specimens for an indefinite period of time only for those specimens collected by the University of Maryland CVD for use in future research at the CVD. \[A University of Maryland site-specific inclusion criterion\]

Exclusion Criteria

1. History of any of the following medical illnesses

* Chronic rhinitis, runny nose, sneezing
* Clinically significant nose bleed within the last year
* Diabetes
* Cancer
* Heart disease (hospitalization for a heart attack, arrhythmia, or syncope)
* Unconsciousness (other than a single brief "concussion")
* Seizures (other than febrile seizures as a child \<5 years old)
* Recurrent infections (more than 3 hospitalizations for invasive bacterial infections such as pneumonia or meningitis)
* Asthma requiring treatment with inhaler or medication
* Any current illness requiring daily medication other than vitamins, birth control, or anti-depressant
2. Blood Type B or AB, regardless of Rh + or -
3. Allergies or hypersensitivity to chitosan, shrimp, other shellfish or any component of the vaccine, adjuvant/excipients or placebo
4. History of nasal surgery of any type (including tonsilectomy/adenoidectomy)
5. Any clinically significant abnormality detected on physical examination, including:

* Murmur (other than a functional murmur)
* Focal neurological abnormality
* Hepatosplenomegaly
* Lymphadenopathy
* Jaundice
6. Hypertension (BP \> 140/90 mm Hg on two separate days)
7. Any lab abnormality, as listed below:

* Neutrophils (WBC) outside the normal range
* Hemoglobin outside the normal range (may be repeated once if outside this limit)
* Platelet count outside the normal range (may be repeated once if outside this limit)
* Creatinine outside the normal range (may be repeated once if outside this limit)
* Glucose \> upper limit of normal (may be repeated once if outside this limit)
* AST or ALT outside the normal range (may be repeated once if outside this limit)
* Positive serology for hepatitis C or HIV antibody or hepatitis B surface antigen
8. For women, positive serum pregnancy test within 7 days and urine pregnancy test within 24 hours of administering either dose of Norwalk VLP Vaccine, adjuvant/excipients or placebo
9. Nursing mother
10. Temperature \> 38.0 degrees C (100.4 degrees F) or symptoms of an acute self-limited illness such as an upper respiratory infection or gastroenteritis within 3 days of administration of Norwalk VLP Vaccine, adjuvant/excipients or placebo
11. Previous participation in a study of Norovirus vaccines
12. Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months
13. Receipt of an investigational vaccine or drug within 28 days before administration of Norwalk VLP Vaccine, adjuvant/excipients or placebo
14. Other condition that in the clinical judgment of the investigator would jeopardize the safety or rights of a subject participating in the trial, would render the subject unable to comply with the protocol or would interfere with the evaluation of the vaccine
15. Failure to pass written examination about this study (70% correct answers required to pass)\[A University of Maryland site-specific exclusion criterion\]

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes